A novel therapy with a rational design for AML
In this issue of Blood, Liu et al1 report the results of a phase 1 clinical trial using pegcrisantaspase (PegC) in combination with venetoclax in relapsed
Related Articles
Tandem CD20-CD19-Directed CAR T-Cell Therapy for Relapsed/Refractory DLBCL: Zamtocabtagene Autoleucel
Nirav Shah, MD, discusses findings from an interim analysis of the phase 2 DALY II trial, which is the first pivotal trial evaluating tandem CD20-CD19…
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck
Nature Reviews Clinical Oncology – Accumulating evidence indicates that NUT carcinoma, a highly aggressive malignancy driven by NUTM1 fusions, is a rare form of squamous…
Fox Chase Cancer Center’s Austin Williams Named 2025 Society of Surgical Oncology Presidential Scholar
Austin D. Williams, MD, MSEd, FACS, was recently named a Presidential Scholar by the Society of Surgical Oncology.
Imetelstat: a new addition to the therapeutic landscape of lower-risk MDS
Imetelstat is an oligonucleotide telomerase inhibitor recently approved by the US Food and Drug Administration for adults with lower-risk myelodysplasia wh
Myelofibrosis Disease Biology: From Molecular Mechanisms to Clinical Phenotypes and Therapeutic Targets
Panelists discuss how myelofibrosis progresses from its molecular and genetic origins through various clinical manifestations, ultimately informing the development of targeted therapeutic approaches for this…
Azenosertib Monotherapy Yields Encouraging Responses in Cyclin E1+ PROC
Results from the ZN-c3-001, MAMMOTH, and DENALI trials demonstrated meaningful ORRs with azenosertib in platinum-resistant ovarian cancer.
Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
The combination of botensilimab plus balstilimab elicited high major pathologic response rates with extended time to surgery in resectable colorectal cancer.
Quantifying MM disease burden by BCMA?
In this issue of Blood, Ikeda and colleagues successfully demonstrated the utility of soluble B-cell maturation antigen (sBCMA) as a quantitative metric fo
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
